

# **Internship Report**

Submitted to



**IIHMR University, Jaipur**

**Master of Business Administration (MBA)**

**In**

**Pharmaceutical Management**

By

**Sanket Surendra Khutade**

**IIHMR-U/02/2022-24/0432**

**MBA PM-14**

Under the Supervision & Guidance of

**Dr. Saurabh Kumar Banerjee**

Dean of School of Pharmaceutical Management

IIHMR University, Jaipur

2024

# MSN Laboratories Pvt Ltd.

## About MSN Laboratories

MSN Laboratories Pvt. Ltd, established in 2003, is headquartered in Hyderabad, India. The company specializes in the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). With a commitment to quality and innovation, MSN Laboratories has grown rapidly to become a key player in the pharmaceutical sector. The company's mission is to make affordable healthcare accessible globally through high-quality pharmaceutical products.

## History and Milestones

MSN Laboratories has achieved significant milestones since its inception. Some key historical highlights include:

- **2003:** MSN Laboratories was founded with a focus on developing APIs.
- **2005:** The company launched its first API product, marking its entry into the pharmaceutical market.
- **2008:** Expansion into finished dosage forms began, broadening the company's product offerings.
- **2010:** MSN received regulatory approvals for its products in various international markets, including the US and Europe.
- **2015:** The company established a state-of-the-art research and development (R&D) center to bolster its innovation capabilities.
- **2020:** MSN Laboratories expanded its global footprint, exporting products to over 65 countries.

## Product Portfolio and Market Presence

MSN Laboratories boasts a diverse product portfolio, including over 250 APIs and more than 120 finished dosage forms. The company's products cater to various therapeutic categories, such as oncology, cardiology, diabetology, gastroenterology, and central nervous system (CNS) disorders.

## **Global Presence:**

- MSN Laboratories exports its products to over 65 countries, with a strong presence in markets like the USA, Europe, Asia, and Latin America.
- The company has established partnerships with leading pharmaceutical companies worldwide, enhancing its market reach and product distribution.
- MSN hold a global rank 1<sup>st</sup> in manufacturing the highest number of API
- MSN holds a global rank 1<sup>st</sup> in USD DMF filing overtaking established giant pharmaceutical companies.
- MSN is a quality pharma company that brings 350+ bioequivalent branded generics at an affordable cost for Indian patients & worldwide including 40+ molecules first time in India.

## **Financial Performance and Assets**

MSN Laboratories has demonstrated robust financial performance over the years. Key financial highlights include:

- **Revenue Growth:** The company has achieved consistent revenue growth, driven by its expanding product portfolio and market reach.
- **Profitability:** MSN maintains healthy profit margins, reflecting its efficient operational management and cost-effective manufacturing processes.
- **Assets:** The company's assets include state-of-the-art manufacturing facilities, advanced R&D centers, and a skilled workforce. These assets underpin MSN's competitive advantage in the pharmaceutical industry.

## **Research and Development**

Research and development (R&D) is a cornerstone of MSN Laboratories' success. The company invests significantly in R&D to drive innovation and develop new and improved pharmaceutical products. Key aspects of MSN's R&D efforts include:

- **Innovation:** MSN focuses on developing innovative formulations and drug delivery systems to enhance therapeutic outcomes.

- **Regulatory Compliance:** The company's R&D initiatives adhere to stringent regulatory standards, ensuring the safety and efficacy of its products.
- **Collaborations:** MSN collaborates with academic institutions and research organizations to leverage cutting-edge scientific knowledge and technologies.

### **Future Growth and Prospects**

MSN Laboratories is poised for continued growth and expansion. Key drivers of future growth include:

- **Product Diversification:** The company aims to diversify its product portfolio further by entering new therapeutic areas and developing complex generics.
- **Geographical Expansion:** MSN plans to strengthen its presence in emerging markets while expanding its footprint in established markets.
- **Technological Advancements:** The company is investing in advanced manufacturing technologies and digital solutions to enhance operational efficiency and product quality.
- **Sustainability:** MSN is committed to sustainable business practices, focusing on environmental stewardship and social responsibility.

Our achievements are a testament to the hard work, dedication, and unwavering commitment to innovation, which resonates purpose in all our endeavours by the team of 2200+ scientists at Asia's largest state-of-the-art research & development centre having 900+ patents led by our founder and chairman Dr M S N Reddy who himself is accomplished research chemistry scientist.

We are also a proud Indian company that has 21 + manufacturing facilities at Hyderabad and in the US with 30+ approvals including US FDA, UK MHRA & WHO GMP exporting to 80+ countries.

MSN augments the walk distance of Indian PAH and rheumatology patients with the first-time in India launches of PAH drugs and affordable Tofacitinib Tofadoz for RA patients.

At MSN we believe that each life matters and deserve quality medicine at an affordable cost. So we were the first to launch treatment options for orphanage indications like MS, Wilson disease, Thalassemia & Mucormycosis.

MSN revolutionized affordable Onco-care with first time-in-India launches translating unaffordability to affordability.

In the country of youth, our culture is to respect the elders and for the ageing population, we made life king-size with First-time in India for BPH and OAB.

MSN has evolved as the decade's most innovative cardiology company easing the flow and pumping strong with affordable First-time in India for hypernatremia, heart failure, antiplatelets & anticoagulants ensuring long-term therapy adherence.

MSN broke the barrier of unaffordability & emerged as the decade's most innovative metabolic company through the launch of affordable DP4 & SGLT2 inhibitors & played a pioneering role for Indian diabetic patients & broke the MNC dominance.

The endeavour of restoring smiles continues with the launch of the FIRST-TIME IN INDIA pain portfolio in both acute & chronic.

As the saying goes “your stomach before anything else” The gut going matters with MSN FIRST-TIME IN INDIA launches like anytime PPI DDR & more.

MSN simplifies happy living for all fellow Indians who suffer from mental health with FIRST-TIME IN INDIA launches.

MSN helps in overcoming & winning over seizure worry fear with new generation First-time in India - anti-epileptic drugs.

India is a country known for women's courage & valour, restoring her health- pale to pink with FIRST-TIME IN INDIA launches exclusively for her giving us immense satisfaction.

As we mark this milestone of 20 years, we celebrate the extraordinary achievements we have accomplished together let us eagerly embrace the opportunity to shape a brighter & healthier future for Indian patients with affordable original bioequivalent medicines and we are poised to continue our legacy of innovation, discovery, and compassion.